Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin-based pharmacotherapy for Autism Spectrum Disorders
2014-000586-45Phase 4Completed
- Sponsor
- KU Leuven
- Start
- Mar 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4 trial of oxytocin in Autism Spectrum Disorder (ASD), sponsored by KU Leuven. Primary endpoint: Neural and behavioral effects of oxytocin on social functioning. Started Mar 2014; status: completed.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2014-000586-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000586-45.